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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is neratinib? 
A0022 Who manufactures neratinib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has neratinib received marketing authorisation? 
Health problem and current use 
A0002 What is breast cancer? 
A0004 What is the natural course of breast cancer? 
A0006 What are the consequences of breast cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of breast cancer? 
A0003 What are the known risk factors for breast cancer? 
A0024 How is breast cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is breast cancer currently managed according to published guidelines and in 
practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of neratinib on mortality? 
D0005 How does neratinib affect symptoms and findings (severity, frequency) of breast cancer? 
D0006 How does neratinib affect progression (or recurrence) of breast cancer? 
D0011 What is the effect of neratinib on patients ̕ body functions? 
D0012 What is the effect of neratinib on generic health-related quality of life? 
D0013 What is the effect of neratinib on disease-specific quality of life? 
Safety 
C0008 How safe is neratinib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying neratinib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of neratinib? 
A0021 What is the reimbursement status of neratinib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Neratinib/HKI-272 
 
B0001: What is neratinib? 
Neratinib is an irreversible pan-human epidermal growth factor receptor 
(HER) inhibitor. It targets the tyrosine-kinase activity of the epidermal 
growth factor receptors EGFR/HER1, HER2 and HER4. Neratinib activates 
downstream signalling pathways and reduces phosphorylation through the 
inhibition of tyrosine-kinase activity at the intracellular domain of the HER 
receptors [2-4].  
In clinical trials, 240 mg of oral neratinib were administered continuously 
once daily for 12 months until disease recurrence, new breast cancer or in-
tolerable adverse events (AEs). 
 
A0022: Who manufactures neratinib? 
Puma Biotechnology, Inc. 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Neratinib is indicated for patients with early-stage HER2-positive breast 
cancer, who had received trastuzumab-based adjuvant therapy. 
 
 
 
4 Current regulatory status 
A0020: For which indications has neratinib received marketing authorisa-
tion? 
Neratinib has not yet received marketing authorisation from the US Food 
and Drug Administration (FDA) or from the European Medicines Agency 
(EMA) for any indication. However, Puma Biotechnology, Inc. has submit-
ted a New Drug Application for neratinib to the FDA. 
 
irreversible pan-HER 
inhibitor 
once daily 240 mg orally 
for patients with HER2-
positive breast cancer 
not authorised for 
marketing in the US and 
in Europe 
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5 Burden of disease 
A0002: What is breast cancer? 
Owing to the molecular pathogenesis of breast cancer, it is designated as a het-
erogeneous malignancy. It arises from the tissues of the breast and most 
commonly originates in the cells that line the ducts due to dysregulation of 
the cell cycle. Breast cancer can be characterised by the pattern of expression 
of the hormone receptors (oestrogen receptor [ER] and progesterone receptor 
[PR]), the HER2 receptor, a clinically relevant third molecular marker, the 
stage of diagnosis and the rate of growth [5, 6]. Prognostically and therapeu-
tically, a distinction can be made between precancerous conditions like in situ 
tumours (obligatory precancerous condition: ductal carcinoma in situ [DCIS]; 
optional precancerous condition: lobular carcinoma in situ [LCIS]) and inva-
sive breast cancer. 
 
A0004: What is the natural course of breast cancer? 
Mostly, cancer begins in the cells of the ducts, called ductal carcinoma. Ab-
normal cells are found in the lining of the ducts; however, they have not 
spread into the surrounding tissue and thus state a precancerous condition 
like DCIS (stage 0) [7, 8]. Normally, LCIS accompanies with DCIS, whereas 
aggressive subtypes often do not show DCIS. In fact, the development of 
type A, ductal hyperplasia over DCIS, into invasive breast cancer is not veri-
table. Invasive breast cancer (stage I) is restricted to the area where the first 
abnormal cells arose. In stage II, abnormal cells have spread beyond the 
ducts or glands into the breast tissue (invasive ductal carcinoma [IDC] or 
invasive lobular carcinoma [ILC]). Stage III breast cancer is stratified ac-
cording to the tumour size and includes tumours >5 cm involving the skin, 
underlying muscle, lymph nodes or inflammatory breast cancer (IBC) [9]. If 
the cancer has spread to distant parts of the body (stage IV) via the lymph 
system or the blood, it can also be referred to as metastatic breast cancer 
(MBC) [7].  
Breast cancer can be staged by using the American Joint Committee on Can-
cer (AJCC) tumour node metastasis (TNM) staging system. It involves im-
portant tumour characteristics as well as survival data to support the estima-
tion of outcomes. The TNM staging system classifies tumours on the basis of 
primary tumour characteristics (T), the presence or absence of regional 
lymph node involvement (N), and the presence or absence of distant metas-
tases (M) [10]. The TNM staging system is especially relevant for inflamma-
tory and stage IV breast cancer.  
 
A0006: What are the consequences of breast cancer for the society? 
Due to the aging population and in combination with the fact that higher 
age is a main risk factor for cancer, the incidence of cancer will increase over 
time [11]. Globally, around 30.0% of the patients with early breast cancer 
develop advanced or MBC [9]. In Austria, breast cancer accounts for approx-
imately 28,000 (2.6% of total) life-years lost due to premature deaths [12]. 
Moreover, the incidence of breast cancer is highest for higher socioeconomic 
groups, whereas survival is lowest in lower socioeconomic groups [13]. 
heterogeneous disease 
that arise from the 
tissue of the breast 
stages of breast cancer 
AJCC-TNM staging 
system 
increasing incidence of 
cancer 
 
 
highest incidence rate in 
higher socioeconomic 
groups 
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A0023: How many people belong to the target population? 
About 30% of all malignant neoplasm cases in Austria are due to breast can-
cer. It is the most common cause of death due to cancer in females. The age 
standardised incidence rate for the European Standard Population (2013) is 
64.3 per 100,000 persons per year. In 2014, 5,454 persons were newly diag-
nosed with breast cancer in Austria, of whom approximately 98.0% were 
women. Moreover, around 86.0% of female breast cancer patients and 78.0% 
of male breast cancer patients (all stages are included) are alive at least five 
years after diagnosis [14]. The median age at diagnosis of breast cancer is 62 
years, ranging from 55 to 64 years [15]. HR-positive disease accounts for ap-
proximately 65.0% and 80.0% of breast cancers in pre- and postmenopausal 
women, respectively, and 15.0% to 23.0% of all breast cancer patients have 
HER2 disease [16]. 
 
A0005: What are the symptoms and the burden of breast cancer? 
A hard, immovable, single dominant lesion (breast mass) with irregular bor-
ders is the most common symptom of breast cancer [15, 17, 18]. In addition, 
symptoms like swelling of the whole or only parts of the breast, skin irrita-
tion or dimpling (peau d’orange), breast or nipple pain, nipple retraction, 
redness, scaliness, or thickening of the nipple or breast skin, nipple dis-
charge or axillary adenopathy can occur [15, 18, 19]. In advanced stages of 
breast cancer weight loss and reduced performance can be present [19]. 
Symptoms due to metastases include swelling of the arm by lymphedema in 
lymph node metastases of the axilla, bone pain in skeletal metastases, cough 
and dyspnoea in pulmonary and/or pleural metastases, jaundice and hepatic 
failure in advanced liver metastases, or neurological symptoms in cerebral 
metastases [15, 19, 20]. 
 
A0003: What are the known risk factors for breast cancer? 
Established high-risk factors for developing breast cancer are an increasing 
age, female gender and white race. Indeed, obesity as well as certain genes 
like BRCA2, BRCA1 and TP53 are associated with an increased risk of 
breast cancer in premenopausal and postmenopausal women [19-23]. In ad-
dition, increased exposure to oestrogen like menarche or late menopause can 
also be a risk factor for the diagnosis of breast cancer [19, 21]. Furthermore, 
reproductive factors that increase risk are a first pregnancy at late age, ab-
sence of breastfeeding and nulliparity [21, 22]. Other risk factors that may 
lead to breast cancer are alcohol consumption, smoking, family and personal 
history of breast cancer [22]. 
 
 
 
 
 
 
 
incidence rate based on 
the European Standard 
Population: 64.3 per 
100,000 persons/year 
 
 
 
 
median age at diagnosis: 
62 years 
main symptoms: 
breast mass,  
skin irritation, 
pain 
main risk factors:  
age, gender, race, 
obesity, genes, 
menopausal status 
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A0024: How is breast cancer currently diagnosed according to published 
guidelines and in practice? 
There are several ways to diagnose breast cancer, such as the clinical breast 
exam (CBE), the x-ray mammography or radiological examinations like the 
ultrasound exam or magnetic resonance imaging (MRI). However, an ab-
normal mammogram detected in countries with established screening pro-
grams is the most common reason for suspecting breast cancer. Additionally, 
blood chemistry studies or biopsies can be conducted. If breast cancer is 
suspected via a mammography, a biopsy (punch biopsy and vacuum-assisted 
biopsy) and a sonography (in women ≤40 years) are performed. An addi-
tional breast MRI can increase the detection rate of additional lesions, but it 
does not improve the prognosis [19]. In the later stage of the disease, liver 
function tests, brain MRIs, abdominal diagnostic scans, bone scans, sodium 
fluoride positron emission tomographies (PETs) or fluorodeoxyglucose 
(FDG) can be applied [24]. 
As breast cancer is a heterogeneous disease, it is essential to establish the 
HR and HER2 status [7, 24]. Additionally, the stratification into the differ-
ent disease stages, described in the section “A0004: What is the natural 
course of breast cancer?” is crucial to ensure the best therapy.  
 
 
 
6 Current treatment 
A0025: How is breast cancer currently managed according to published 
guidelines and in practice? 
In general, breast cancer can be treated by radiotherapy, surgery and sys-
tematic therapies [19]. To determine which treatment strategy is the most 
suitable for the patient, several factors are important [19, 25]: 
 stage of cancer (AJCC TNM staging system) 
 grade of disease 
 tumour site 
 menopausal status 
 patient health 
 HER2 and HR status 
 proliferation rate estimated by means of a Ki67 test 
The treatment of stage ≤3 breast cancer, where no distant metastases have 
been detected, has a curative intention and is dependent on the eligibility of 
a breast-conserving therapy (BCT) and whether it is a clinically node-
negative or node-positive breast cancer. For patients who are eligible for a 
BCT, the following treatment options (in this sequence) may be applied 
[19]:  
 primary neoadjuvant systematic therapy (node-negative breast can-
cer)  
 surgery (sentinel lymph node biopsy [SLNB]) 
 axillary node dissection 
 adjuvant systematic therapy  
 adjuvant radiation therapy 
diagnosis of breast 
cancer via 
mammography, CBE, 
biopsy, blood chemistry 
and x-ray tests 
 
additional use of MRI 
possible to detect 
further lesions 
HR and HER2 status 
 
stratification into 
disease stage 
factors for therapeutic 
decisions 
durative treatment 
options for stage ≤3 
breast cancer 
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For patients who are not eligible for a BCT and for locally advanced breast 
cancer (stage IIB, IIIA/B), the previously mentioned treatment options can 
be applied as well. However, instead of a BCT, a mastectomy may be ap-
plied. In the case of metastatic disease (stage IV), treatment with a palliative 
intent (systematic therapy, best supportive care, etc.) can be used [19].  
Adjuvant treatment options for HER2-positive breast cancer (stage II-III) 
are [19, 26]: 
 adjuvant radiation therapy 4–6 weeks after surgery  
 adjuvant endocrine therapy for HR-positive patients  
o premenopausal women: tamoxifen or tamoxi-
fen/exemestane and eliminating or suppressing ovarian 
function  
o postmenopausal women: aromatase inhibitors (e.g., anas-
trozole, letrozole, exemestane) and tamoxifen 
 adjuvant therapy with trastuzumab (>1 year) in combination or se-
quentially with chemotherapy; weekly treatment with paclitaxel in 
elderly patients or node-negative breast cancer can be used instead 
of chemotherapy 
 
 
 
7 Evidence 
A literature search was conducted on 27 December 2016 in five databases: 
the Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Neratinib”, “HKI-272”, “breast cancer”, “breast neo-
plasms” and “mamma carcinoma”. The manufacturer was also contacted 
and submitted three references (two of which had already been identified by 
systematic literature search). A manual search identified 21 additional refer-
ences (web documents and journal articles). Overall, 397 references were 
identified. Included in this reported are:  
 One phase III study, assessing neratinib in early-stage HER2-
positive breast cancer patients who had received trastuzumab-
based adjuvant therapy [27, 28] 
 One phase II study, assessing neratinib in patients with advanced 
HER2-positive breast cancer [29] 
The methodological quality of the evidence was conducted to assess the risk 
of bias at the study level based on the EUnetHTA internal validity for RCTs 
[26, 30]. Evidence was assessed based on the adequate generation of the ran-
domisation sequence, allocation concealment, blinding of patient and treat-
ing physician, selective outcome reporting and other aspects that may in-
crease the risk of bias. Study quality details are reported in Table 5 of the 
Appendix. 
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [31]. Additionally, an adapted version (due to perceived 
stage IV breast cancer 
treatment options with 
a palliative intent 
 
 
 
adjuvant treatment 
strategies 
systematic literature 
search in 5 databases: 
376 hits 
included: 1 phase III and 
1 phase II study 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
 
Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy 
LBI-HTA | 2017 11 
limitations) of the ESMO-MCBS was applied [32]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety –  
phase III studies 
The ExteNET trial (a randomised, multicentre, double-blind, placebo-
controlled phase III study) was conducted to assess the efficacy and safety of 
neratinib after trastuzumab-based adjuvant treatment in patients with early 
stage HER2-positive breast cancer [27, 28].  
A total of 2,840 women were randomly assigned in a 1:1 ratio to receive ei-
ther neratinib (n = 1,420; 240 mg daily) or matching placebo (n = 1,420). 
The stratification of randomisation (permuted block randomisation) was 
based on the hormone receptor status (hormone receptor-positive [OR- or 
PR-positive or both] vs. hormone receptor-negative [OR- and PR-negative]), 
nodal status (0, 1–3, or ≥4), and trastuzumab adjuvant regimen (sequential-
ly vs. concurrently with chemotherapy). It was centrally implemented by an 
interactive voice and web-response system. Patients, investigators, caregiv-
ers, outcome assessors as well as trial sponsors were masked to treatment al-
location. 
On 25 February 2010 a global amendment of the study was done to restrict 
the recruitment to higher-risk patients who were defined as patients with 
node-positive disease and had completed prior trastuzumab therapy for up 
to one year. 1,580 patients had already been recruited until 25 February 
2010. After the changes had been applied, 1,248 further patients were en-
rolled. Therefore, the efficacy population was changed from the intention-to-
treat (ITT) to the amended ITT (aITT). Two additional changes were ap-
plied in 2011: to cease enrolment and to shorten follow-up from five years to 
two years from randomisation. As of January 2014 the study was continued 
with this design until the current sponsor changed the population of the 
primary endpoint back to the ITT of the original protocol. 
Enrolled patients had a median age of 52 years. The study population had an 
Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, 
normal organ function and a left ventricular ejection fraction within normal 
institutional range. Patients had to have locally confirmed invasive HER2-
positive breast cancer without evidence of recurrence. At 24 months follow-
up, central HER2 testing was performed in 1,705 (60%) of primary tumour 
specimens. The HER2 status was confirmed centrally using the PathVysion 
HER2 DNA dual probe (Abbott Molecular, Des Plaines, IL, USA). The 
HER2 amplification was defined as a ratio of HER2 to CEP17 of ≥2.2. De-
tailed patient characteristics, together with including inclusion and exclu-
sion criteria, can be found in Table 4 of the Appendix. 
The median follow-up of the study was 24 months (IQR 20–25) in the nerat-
inib group and 24 months (IQR 22–25) in the placebo group. At the time of 
24 months follow-up (July 2014), 70 invasive disease-free survival (DFS) 
events in the neratinib group and 109 DFS events in the placebo group had 
occurred. The primary endpoint of the study was invasive DFS. Secondary 
outcomes included DFS, taking account of ductal carcinoma in situ, cumu-
lative incidence of recurrences in the central nervous system (CNS), overall 
ExteNET: efficacy and 
safety of neratinib in 
2,840 women 
permuted block 
randomisation 
amendments of the 
study protocol 
median age of 52 years 
and ECOG performance 
status of 0–1 
median follow-up:  
24 months 
 
 
primary study endpoint: 
invasive DFS 
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survival (OS) and safety. Health-related quality of life was an exploratory 
endpoint.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of neratinib on mortality? 
At the time of primary analysis OS data was immature, since the target 
number of events had not been reached. Therefore, OS will continue to be 
monitored by the Independent Data Monitoring Committee. 
 
D0006: How does neratinib affect progression (or recurrence) of breast 
cancer? 
After a 24-month follow-up, significantly fewer invasive DFS events had oc-
curred in the neratinib group (70 vs. 109 events). Compared with the place-
bo group, the hazard ratio (HR) for invasive DFS events was 0.67 (95% CI 
0.50–0.91; p = 0.0091). The two-year invasive DFS rate was 93.9% (95% CI 
92.4–95.2) and 91.6% (95% CI 90.0–93.0) in the neratinib and placebo 
groups, respectively. DFS including ductal carcinoma in situ (DCIS) events 
was significantly improved in the neratinib group (93.9%, 95% CI 92.4–95.2) 
compared to the placebo group (91.0%, 95% CI 89.3–92.5) (HR 0.63, 95% CI 
0.46–0.84; p = 0.0017). No statistically significant difference between the 
study groups could be shown for distant DFS and for the time to distant re-
currence. In the neratinib group the two-year incidence of CNS recurrence 
was 0.91% (95% CI 0.49–1.59) and 1.25% (95% CI 0.75–1.99) in the placebo 
group (p = 0.44). The pre-specified subgroup analysis of invasive DFS 
showed a higher improvement in hormone receptor-positive breast cancer 
(HR 0.51, 95% CI 0.33–0.77; p = 0.0013) compared to the population with 
hormone receptor-negative disease (HR 0.93, 95% CI 0.60–1.43; p = 0.74). 
In patients with centrally confirmed HER2-positive breast cancer, invasive 
DFS was significantly improved in the neratinib group (n = 741) compared 
to the placebo group (n = 722, HR 0.51, 95% CI 0.33–0.77; p = 0.0015). 
 
D0005: How does neratinib affect symptoms and findings (severity, frequen-
cy) of breast cancer? 
No evidence was found to answer this research question. 
D0011: What is the effect of neratinib on patients̕ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of neratinib on generic health-related quality of 
life? 
D0013: What is the effect of the neratinib on disease-specific quality of life? 
Two instruments were used to measure quality of life (QoL): the EQ-5D for 
health-related QoL and the Functional Assessment of Cancer Therapy-
Breast, FACT-B for disease-specific QoL. The greatest difference in QoL be-
tween the two study groups was at month one for both measures (EQ-5D, -
2.7 [95% CI -3.7 to -1.7], FACT-B, -2.9 [95% CI -3.7 to -2.0]). In none of the 
immature OS data 
2-year invasive DFS 
rate: 
neratinib: 93.9% 
placebo: 91.6% 
 
 
 
 
 
 
 
 
 
patients with centrally 
confirmed HER2-
positive disease showed 
a significant 
improvement in invasive 
DFS 
no clinically significant 
difference in QoL 
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two study groups was the difference clinically significant and after the first 
month of treatment it declined. 
 
Table 1: Efficacy results of the ExteNET trial (estimated disease-free survival rate at two years) 
Descriptive statistics 
and estimate variability 
Treatment group Neratinib Placebo 
Number of subject 1,420 1,420 
Invasive DFS events, n 70 109 
Invasive DFS, % 93.9 (92.4–95.2) 91.6 (90.0–93.0) 
DFS-DCIS, % 93.9 (92.4–95.2) 91.0 (89.3–92.5) 
Two-year cumulative inci-
dence of CNS recurrence, % 
0.91 (0.49–1.59) 1.25 (0.75–1.99) 
Distant DFS 95.1 (93.7–96.2) 93.7 (92.2–94.9) 
Time to distant recurrence 95.4 (94.1–96.5) 93.9 (92.4–95.0) 
OS NA NA 
Effect estimate per 
comparison 
 
Comparison groups Neratinib versus placebo 
Invasive DFS HR 0.67 
95% CI 90.0–93.0 
Log-rank test p-value 0.0091 
DFS-DCIS HR 0.63 
95% CI 0.46–0.84 
Log-rank test p-value 0.0017 
Distant DFS HR 0.75 
95% CI 0.53–1.04 
Log-rank test p-value 0.089 
Time to distant recurrence HR 0.71 
95% CI 0.50–1.00 
Log-rank test p-value 0.054 
 Two-year cumulative inci-
dence of CNS recurrence 
Gray's test p-value 0.44 
 EQ-5D 
 
AMD of changes in QoL -2.7 
95% CI -3.7 – -1.7 
FACT-B AMD of changes in QoL -2.9 
95% CI -3.7 – -2.0 
Abbreviations: AMD = adjusted mean difference, CI = confidence interval, CNS = central nervous system, DCIS = ductal 
carcinoma in situ, DFS = disease-free survival, FACT-B = Functional Assessment of Cancer Therapy-Breast, HR = hazard 
ratio, NA = not available, QoL = quality of life 
 
7.1.2 Safety 
C0008: How safe is neratinib in relation to the comparator(s)? 
The most common treatment-emergent AE in the neratinib group was diar-
rhoea. In over 90% of patients in the neratinib group diarrhoea of any grade 
occurred. 458 patients (33%) had grade 2 diarrhoea, 561 (40%) grade 3 diar-
rhoea and one patient had grade 4 diarrhoea. In the placebo group 94 pa-
tients (7%) had grade 2 diarrhoea, 23 (2%) had grade 3 diarrhoea and none 
had grade 4 diarrhoea. Moreover, the second most common AEs, nausea 
(grade 1–2: 41%, grade 3: 2%) and fatigue (grade 1–2: 25%, grade 3: 2%) 
were observed in patients of the neratinib arm. QT prolongation occurred in 
49 patients (3%) who received neratinib and in 93 patients (7%) who re-
ceived placebo. 
most common AE: 
diarrhoea 
 
>90% of patients in the 
neratinib group had 
diarrhoea of any grade  
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Serious AEs occurred in 103 patients (7%) of the neratinib group and in 85 
patients (6%) of the placebo group. Four patients in the neratinib group and 
three patients in the placebo group died after study drug discontinuation. Of 
the four patients in the neratinib group, two patients died due to a primary 
tumour (brain and acute myeloid leukaemia). For the other two patients the 
cause of death is unknown. In the placebo group the causes of death for the 
three patients were brain haemorrhage, myocardial infarction and gastric 
cancer.  
 
C0002: Are the harms related to dosage or frequency of applying neratinib? 
Due to diarrhoea, dose reductions were necessary for 372 patients (26%) in 
the neratinib group and for eight patients (1%) in the placebo group, 
hospital admission for 20 patients (1%) versus one patient (<1%), and drug 
discontinuation for 237 patients (17%) versus three patients (<1%). 
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of neratinib? 
HER2-targeted agents are associated with an increased incidence of differ-
ent cardiovascular AEs and gastrointestinal toxicities [33, 34]. Therefore, pa-
tients with a history of gastrointestinal or heart disease could be harmed 
when treated with neratinib. Since neratinib has not been investigated in 
pregnant women, special caution has to be applied in this patient popula-
tion. 
 
Table 2: Most frequent treatment-related adverse events
1
 
 
Adverse Event (according  
to CTCAE version 3.0) 
 
Intervention (n = 1,408) Control (n = 1,408) 
 Grade 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Grade 1–2 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Diarrhoea 781 (55) 561 (40) 1 (<1) 476 (34) 23 (2) 0 (0) 
Nausea 579 (41) 26 (2) 0 (0) 301 (21) 2 (<1) 0 (0) 
Fatigue 359 (25) 23 (2) 0 (0) 276 (20) 6 (<1) 0 (0) 
Vomiting 322 (23) 47 (3) 0 (0) 107 (8) 5 (<1) 0 (0) 
Abdominal pain 314 (22) 24 (2) 0 (0) 141 (10) 3 (<1) 0 (0) 
Headache 269 (19) 8 (1) 0 (0) 269 (19) 6 (<1) 0 (0) 
Upper abdominal pain 201 (14) 11 (1) 0 (0) 93 (7) 3 (<1) 0 (0) 
Rash 205 (15) 5 (<1) 0 (0) 100 (7) 0 (0) 0 (0) 
Decreased appetite  166 (12) 3 (<1) 0 (0) 40 (3) 0 (0) 0 (0) 
Muscle spasms 157 (11) 1 (<1) 0 (0) 44 (3) 1 (<1) 0 (0) 
Dizziness 143 (10) 3 (<1) 0 (0) 125 (9) 3 (<1) 0 (0) 
Arthralgia 84 (6) 2 (<1) 0 (0) 158 (11) 4 (<1) 0 (0) 
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events 
                                                             
1
 Treatment-related adverse events occurring in at least 10% of patients in the safety 
population (patients who have received at least one dose of study treatment). 
SAEs: 
neratinib:  
103 patients (7%) 
placebo: 
85 patients (6%) 
dose reductions due to 
diarrhoea: 
neratinib: 26% 
placebo: 1% 
 
gastrointestinal & 
cardiovascular toxicities 
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7.2 Clinical effectiveness and safety –  
further studies 
Neratinib has not been investigated in any additional phase II or III trial for 
this specific indication and patient population before. However, a multicen-
tre, open-label, phase II trial [29] evaluated the safety and efficacy of nerat-
inib in two patient cohorts with advanced HER2-positive breast cancer. Pa-
tients in cohort A received prior trastuzumab-based treatment and patients 
of cohort B did not receive prior trastuzumab treatment. A total of 66 pa-
tients were included in cohort A and 70 patients were enrolled in cohort B. 
The daily administered oral dose of neratinib was 240 mg. The primary end-
point was a 16-week PFS rate assessed by independent review; secondary 
endpoints included objective response rate, safety and duration of response. 
The 16-week PFS rate in patients of cohort A was 59% and 78% for patients 
of cohort B. The median PFS was 22.3 weeks and 39.6 weeks, respectively. 
The objective response rate for patients of cohort A was 24% and 56% for 
patients of cohort B. The most frequent AEs were diarrhoea, nausea, vomit-
ing and fatigue. The most common grade 3–4 AE was diarrhoea, occurring 
in 30% of patients of cohort A and in 13% of patients of cohort B. This con-
sequently led to discontinuation in 29% and 4% of patients, respectively.  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of neratinib? 
Since neratinib has not yet received marketing authorisation in Europe or in 
the US for any indication, no price estimates are available at the moment. 
Additional costs will incur due to the monitoring of blood tests, as well as for 
monitoring and managing toxicities owing to neratinib (e.g., cardiotoxicities 
and gastrointestinal toxicities) [33-35].  
 
 
 
9 Ongoing research 
In January 2017, a search in databases http://clinicaltrials.gov/ and 
https://www.clinicaltrialsregister.eu/ctr-search/ was conducted. The follow-
ing ongoing phase III trial is investigating neratinib in HER2-positive breast 
cancer patients: 
 NCT00878709: A study of neratinib plus capecitabine versus lapa-
tinib plus capecitabine in patients with HER2-positive metastatic 
breast cancer who have received two or more prior HER2 directed 
efficacy and safety of 
neratinib in advanced 
HER2-positive breast 
cancer 
16-week PFS rate 
cohort A: 59% 
cohort B: 78% 
no price estimates 
available for Austria 
one ongoing phase III 
study investigating 
neratinib in HER-
positive breast cancer 
patients 
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regimens in the metastatic setting. Estimated study completion 
date is May 2018. 
Currently, various phase I and II studies are ongoing in different treatment 
lines in patients with breast cancer, either using neratinib monotherapy or 
combination treatment (e.g., NCT01494662, NCT01008150, NCT00398567, 
and NCT00777101). 
 
 
 
10 Discussion 
Neratinib is not approved for any indication in the US or in Europe at pre-
sent. However, Puma Biotechnology, Inc. has submitted a New Drug Appli-
cation to the FDA concerning neratinib for the extended adjuvant treatment 
of patients with early stage HER2-overexpressed breast cancer who have re-
ceived prior adjuvant trastuzumab-based therapy. 
A randomised, multicentre, double-blind, placebo-controlled phase III 
study, ExteNET [27, 28], compared neratinib with placebo in patients with 
early-stage HER2-positive breast cancer after prior trastuzumab-based adju-
vant therapy. The study enrolled a total of 2,840 women. After 24 months 
significantly fewer invasive DFS events occurred in the neratinib group (70 
vs. 109 events, p = 0.0091). The two-year invasive DFS rate was 2.3% higher 
in the overall population of the neratinib group and 2.9% higher in patients 
with DCIS compared to the placebo group. Patients with hormone receptor-
positive disease showed a higher improvement in invasive DFS compared to 
hormone receptor-negative patients (HR 0.51 vs. 0.93). QoL data showed no 
clinical significant difference between the two study groups. OS data was 
immature at the time of analysis. 
Criticism has risen in regard to the use of the HR to demonstrate treatment 
benefit in clinical trials. It could be possible that the HR has no meaningful 
clinical benefit, since estimations of hazard functions for each study group 
are challenging without modelling over time [36-38]. A correspondence from 
Hasegawa and Uno [39] implied that the stated 24-month invasive DFS rate 
might not gather the overall patient profile. They suggested to alternatively 
use the restricted mean survival time to quantify and better illustrate the 
treatment benefit, whereby survival means invasive DFS. They estimated 
the restricted mean survival time for neratinib (calculating the area under 
the Kaplan-Meier curve) to be 23.5 months and 23.0 months for the placebo 
group. This would imply that patients treated with neratinib for 24 months 
show a mean invasive DFS of 23.5 months, which is a gain of 0.5 months 
compared to the placebo group. 
A study (HERA trial) of one-year trastuzumab treatment compared to obser-
vation alone in 3,399 patients showed a decline in efficacy over an eight-year 
follow-up period [40]. Therefore, to verify the current findings of neratinib, 
mature OS data as well as further follow-up data are needed. In addition, to 
better reflect the most affected patient population, neratinib should also be 
investigated in an older patient population (median age of study population: 
52), as the median age of breast cancer diagnosis is 62 years [41].  
not approved in Europe 
and US 
ExteNET: 
significantly fewer DFS 
events 
 
OS data and DFS in 
months were not 
available 
 
no clinical significant 
difference in QoL 
0.5 month gain of the 
restricted mean survival 
time compared to the 
placebo group 
further follow-up and 
mature OS data needed 
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With regard to safety outcomes, grade 3–4 AEs occurred more commonly in 
patients of the neratinib group. The most frequent grade 3–4 AE in the 
neratinib group was diarrhoea (neratinib: 41% vs. placebo: 2%). The second 
most common events of any grade were nausea (43% vs. 23%), fatigue (27% 
vs. 21%) and vomiting (26% vs. 9%). Owing to diarrhoea, dose reductions in 
380 patients of both study groups were necessary, of whom 372 patients 
belong to the neratinib group. Drug discontinuation was applied in 237 
patients (17%) of the neratinib group versus three patients (<1%) of the 
placebo group. 
Over 90% of the patients in the neratinib group have experienced diarrhoea 
of any grade. A current study (CONTROL trial [42]) is investigating wheth-
er the additional administration of loperamide to neratinib can reduce the 
incidence and severity of diarrhoea in patients with early stage HER2-
positive breast cancer. Although loperamide may reduce the risk of gastroin-
testinal toxicities, it is associated with other side effects as well, in particu-
lar, including special precautions for combinations with other drugs that are 
known to prolong the QT interval (neratinib: 3% of patients). Moreover, 
loperamide used concomitantly with CYP3A4 or CYP2C8 inhibitors has also 
shown to increase the risk of cardiac AEs [43].  
Currently, approved targeted therapies (e.g., trastuzumab, lapatinib and 
bevacizumab) for the treatment of breast cancer have demonstrated in-
creased incidences of cardiovascular events [33, 35]. Although neratinib does 
not seem to be associated with the increased risk of cardiac toxicity, scarce 
clinical experience is currently available. A longer follow-up period and a 
greater number of treated patients will therefore be needed to exclude any 
toxic effects on the cardiovascular system. 
The ExteNET trial included patients who received neoadjuvant and/or ad-
juvant trastuzumab-based treatment. In addition, pertuzumab is currently 
under investigation in combination with trastuzumab and chemotherapy in 
an adjuvant treatment setting (APHINITY trial [44]) for HER2-positive 
breast cancer. Pertuzumab is already used in a neoadjuvant setting in com-
bination with trastuzumab and chemotherapy for the treatment of adult pa-
tients with HER2-positive, locally advanced, inflammatory, or early stage 
breast cancer at high risk of recurrence [45]. If pertuzumab plays a prospec-
tive role in the adjuvant treatment of HER2-positive breast cancer, it will be 
important to verify whether the effect of neratinib is also applicable for pa-
tients who received prior pertuzumab-containing treatment. Moreover, a 
comparison of adjuvant pertuzumab-containing treatment and sequential 
neratinib treatment could help to identify the best treatment sequence for 
this patient population. 
The identification of the appropriate patient population will be of high in-
terest in the future. For patients who have HER2-positive and hormone re-
ceptor-positive breast cancer, neratinib therapy was more beneficial than in 
patients with the hormone receptor-negative disease. However, for the prop-
er patient selection biomarkers will be needed to predict the response and 
resistance to neratinib. Further data will also be required to define patients 
who are likely to benefit the most [46, 47].  
most common grade ≥3 
diarrhoea: 41% vs. 2% 
 
dose reductions due to 
diarrhoea: 
26% vs. 1% 
reducing the incidence 
of diarrhoea may lead to 
additional cardiac AEs 
targeted therapies are 
associated with cardiac 
toxicities 
role of pertuzumab in 
the adjuvant treatment 
setting 
biomarkers in order to 
select the appropriate 
patient population 
Horizon Scanning in Oncology 
18 LBI-HTA | 2017 
No cost estimations are currently available for neratinib in the US or in Eu-
rope, since it has not been approved for any indication yet. In addition, costs 
for possible prospective biomarkers will be incurred and costs due to the 
treatment of potential gastrointestinal and cardiac toxicities will increase. 
Although neratinib offers an improvement in invasive DFS, the gastrointes-
tinal toxicities in combination with possible cardiac toxicities suggest an un-
favourable benefit-risk ratio. Further studies are needed to select the appro-
priate patient population and to verify the long-term benefit, as well as to 
exclude toxic effects of the cardiovascular system. 
 
 
no costs available 
additional costs due to 
biomarker and toxicities 
 
 
unfavourable benefit-
risk ratio 
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Table 3: Benefit assessment based on ESMO-MCBS
3
 and adapted benefit assessment based on ESMO-MCBS [31, 32] 
Abbreviations: AJ = Adjustments, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, PE = primary endpoint, PM = preliminary magnitude of clini-
cal benefit grade, QoL = quality of life  
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
 
                                                             
2
 One level downgrade because >10% grade ≥3 adverse events.   
3
 European Society for Medical Oncology - Magnitude of Clinical Benefit Scale 
ESMO-
MCBS 
Active 
substance 
Indication Intention PE Form 
Efficacy Safety 
AJ FM 
DFS rate 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
adapted 
ESMO-
MCBS 
neratinib early stage 
breast cancer 
adjuvant 
therapy 
DFS 1 intervention: 93.6% 
control: 91.6% 
0.67 
0.50–0.91 
improvement in DFS alone: 
HR 0.65–0.80, without ma-
ture OS data 
B 
+46% grade 3–4 
AEs (-1)2 
ND -1 C 
ESMO-
MCBS neratinib 
early stage 
breast cancer 
adjuvant  
therapy DFS 1 
intervention: 93.6% 
control: 91.6% 
0.67 
0.50–0.91 
improvement in DFS alone: 
HR 0.65–0.80, without ma-
ture OS data 
B - - - B 
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12 Appendix  
Table 4: Characteristics of the ExteNET trial 
Title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicen-
tre, randomised, double-blind, placebo-controlled, phase III trial [27, 28] 
Study identifier NCT00878709, EudraCT number 2008-007345-31, ExteNET 
Design Phase III, randomised, multicentre, double-blind, placebo-controlled trial 
Duration Enrolment: 9 July 2009 to 24 October 2011 
Median follow-up time: neratinib: 24 months (IQR 20–25), 
placebo: 24 months (IQR 22–25) 
For consenting patients long-term survival in a follow-up is 
ongoing. 
Hypothesis 
Superiority 
This study was powered to detect differences in invasive DFS between the two study arms. The planned 
sample size of the study was 3,850 patients to provide 90% power at a two-sided 5% significance level 
for the log-rank test and to detect an HR of 0.7. Due to amendments the enrolment was stopped in Oc-
tober 2011 after 2,842 patients were included in the study. The power was then projected to be 88% 
(HR 0.667) at a two-sided 5% significance level. 
Funding Puma Biotechnology, Inc. 
Treatments  
groups 
 
Intervention (n = 1,420) Neratinib was administered orally at a daily dose of 240 mg. 
Placebo (n = 1,420) Placebo was administered orally at a daily dose of 240 mg. 
Endpoints and defini-
tions 
 
Invasive disease-free 
survival (primary out-
come) 
 
DFS Invasive DFS two years after randomisation. Invasive dis-
ease was defined as: invasive ipsilateral tumour recurrence, 
invasive recurrence, distant recurrence, or death from any 
cause. 
Disease-free survival 
including ductal carci-
noma in situ 
DFS-DCIS 
Time from randomization to the first occurrence of any DFS 
event or DCIS 
Distant disease-free 
survival  
DDFS Time from randomization to the first distant recurrence or 
death from any cause 
Time to distant recur-
rence  TTDR 
Time between randomization and the date of the first dis-
tant recurrence, or death from breast cancer 
Incidence of CNS re-
currence  
- Time from randomization to central nervous system recur-
rence as the first distant recurrence 
Results and Analysis 
Analysis description Primary analysis 
Efficacy analyses (primary and secondary endpoints) were performed in the intention-to-treat popula-
tion, which was defined as all randomly assigned patients. Safety analyses were performed in the safety 
population, which was defined as all patients who received at least one dose of study treatment. All 
time-to-event endpoints were tested with two-sided log-rank tests stratified by randomisation. To es-
timate HRs with 95% CIs, stratified Cox proportional-hazards models were used. Two-year survival 
rates were estimated by using Kaplan-Meier methods. Gray’s test was used to compare treatments and 
to evaluate CNS recurrences cumulative incidence competing-risk analyses were performed. For the 
QoL evaluation (changes from baseline in QoL scores) an ANCOVA was used, with baseline score as a 
covariate. 
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Title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicen-
tre, randomised, double-blind, placebo-controlled, phase III trial [27, 28] 
Study identifier NCT00878709, EudraCT number 2008-007345-31, ExteNET 
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion  Age ≥18 years (or ≥20 years in Japan) 
 ECOG performance status 0–1 
 Original inclusion criteria: stage I-III HER-2/erbB-2 positive breast 
cancer with node positive and node-negative disease without evi-
dence of recurrence 
 Global amendment Feb 2010: Stage II through IIIC HER-2/erbB-2 posi-
tive breast cancer with node-positive disease without evidence of re-
currence 
 Been treated for early breast cancer with standard of care duration of 
trastuzumab (up to two years, amendment to one year) 
 Could have been treated in a neoadjuvant setting but have not 
reached pCR 
 Patients with normal organ function and a left ventricular ejection 
fraction within normal institutional range 
Exclusion  Positive clinical and radiologic assessments for local or regional recur-
rence of disease at the time of study entry 
 History of heart disease 
 QTc interval >0.45 seconds 
 History of gastrointestinal disease with diarrhoea as the major symp-
tom 
 Patients with psychiatric comorbidities 
 Patients who were unable to swallow oral medications 
 
Characteristics 
 
Intervention 
(n = 1,420) 
Control 
(n = 1,420) 
Median age (range), years 52 (45–59) 52 (45–60) 
Age at randomisation in years, n (%) 
  <35 
  35–49 
  50–59 
  ≥60 
 
46 (3) 
523 (37) 
497 (35) 
354 (25) 
 
55 (4) 
515 (36) 
488 (34) 
362 (25) 
Region, n (%) 
  North America 
  Western Europe, Australia, New Zealand, South Africa 
  Asia Pacific, Eastern Europe, South America 
 
519 (37) 
487 (34) 
414 (29) 
 
477 (34) 
532 (37) 
411 (29) 
Race, n (%) 
  White 
  Black 
  Asian 
  Other 
 
1,165 (82) 
27 (2) 
188 (13) 
40 (3) 
 
1,135 (80) 
47 (3) 
197 (14) 
41 (3) 
Menopausal status at diagnosis, n (%) 
  Premenopausal 
  Postmenopausal 
 
663 (47) 
757 (53) 
 
664 (47) 
756 (53) 
Nodal statusA, n (%) 
  Negative 
  1–3 positive nodes 
  ≥4 positive nodes 
 
335 (24) 
664 (47) 
421 (30) 
 
336 (24) 
664 (47) 
420 (30) 
Hormone receptor status, n (%) 
  Positive (ER-positive, PR-positive or both) 
  Negative (ER and PR negative) 
 
816 (57) 
604 (43) 
 
815 (57) 
605 (43) 
Previous trastuzumab regimen, n (%) 
  Concurrent 
  Sequential 
 
884 (62) 
536 (38) 
 
886 (62) 
534 (38) 
T stage, n (%) 
  T1 
  T2 
  ≥T3 
  Unknown 
  Missing 
 
440 (31) 
585 (41) 
144 (10) 
250 (18) 
1 (<1) 
 
459 (32) 
555 (39) 
117 (8) 
288 (20) 
1 (<1) 
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Title: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicen-
tre, randomised, double-blind, placebo-controlled, phase III trial [27, 28] 
Study identifier NCT00878709, EudraCT number 2008-007345-31, ExteNET 
Analysis population  
(continuation) 
Histological grade of tumour, n (%) 
  Undifferentiated or poorly differentiated 
  Moderately differentiated 
  Well differentiated 
  Unknown 
 
670 (47) 
461 (32) 
76 (5) 
213 (15) 
 
689 (49) 
416 (29) 
65 (5) 
241 (17) 
Previous surgery, n (%) 
  Lumpectomy only 
  Mastectomy 
  Missing 
 
468 (33) 
951 (67) 
1 (<1) 
 
511 (36) 
908 (64) 
1 (<1) 
 Previous radiotherapy, n (%) 
  Yes 
  No 
 
1,130 (80) 
290 (20) 
 
1,150 (81) 
270 (19) 
Previous neoadjuvant or adjuvant therapyB, n (%) 
  Anthracycline only 
  Anthracycline plus taxane 
  Taxane only 
  Non-anthracycline or taxane 
 
136 (10) 
962 (68) 
318 (22) 
4 (<1) 
 
135 (10) 
965 (68) 
316 (22) 
4 (<1) 
Duration of previous adjuvant trastuzumab therapyC 
  months (range) 
  n 
 
11.5 (10.9–11.9) 
1,413 
 
11.4 (10.8–11.9) 
1,416 
Time from last dose of trastuzumab to randomisation 
  months (range) 
 
4.4 (1.6–10.4) 
 
4.6 (1.5–10.8) 
 Concomitant endocrine therapy for hormone receptor-
positive disease D, n (%) 
  Yes 
  Anti-oestrogen only 
  Anti-oestrogen and aromatase inhibitor (sequential) 
  Aromatase inhibitor only 
  Non-anti-oestrogen or aromatase inhibitor 
 
 
760 (93) 
375 (46) 
20 (3) 
362 (44) 
3 (<1) 
 
 
764 (94) 
347 (43) 
34 (4) 
379 (47) 
4 (<1) 
Abbreviations: CNS = central nervous system, ECOG = Eastern Cooperative Oncology Group, ER = oestrogen receptor, IQR = interquartile 
range, pCR = pathological complete response, PR = progesterone receptor, QoL = quality of life, QTc = Corrected QT Interval, 
A
 the number of 
positive nodes at the time of initial diagnosis or surgery, patients with residual invasive disease in the breast, but node-negative disease or unknown 
nodal status in the axilla, after neoadjuvant therapy were included under 1–3 positive nodes. B Number of patients who received neoadjuvant 
chemotherapy was 342 (24%) in the neratinib group and 379 (27%) in the placebo group. 
C 
Patients with missing or partial dates of trastuzumab 
administration were not included in the analysis. 
D
 Based on the number of hormone receptor-positive patients. 
Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) 
[30] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: permuted block randomisation yes 
Adequate allocation concealment: centrally by an interactive voice and web response sys-
tem 
yes 
Blinding:  
double-blind 
Patient yes 
Treating physician yes 
Selective outcome reporting unlikely:  yes 
No other aspects which increase the risk of bias: industry funded, changes in the study pro-
tocol during the study (patient number, patient population …) 
no 
Risk of bias – study level low 
 
